Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ: CRBP · Life Sciences · 6 alerts · CIK 1595097

Share price
$3.38Close, Nov 16
Market cap
$69.5M
Shares outstanding
20.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Corbus Pharmaceuticals Holdings, Inc. filings on SEC EDGAR ↗

4:36 PM ET 10-Q
Financial Results

Corbus Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $37.8M, Loss Widens

Corbus Pharmaceuticals reported a net loss of $95.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses related to its ADC and obesity pipelines. The company's cash and investment position decreased to approximately $115.3 million from $163.3 million at the end of 2025, despite raising $27.6 million through common stock issuances.

Key figure
Net loss $37.8M
8:08 AM ET 8-K
Financial Results

Corbus Pharmaceuticals Holdings Financial Results

Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.

“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.